Evidence map›Paper›PMID 25406756›Full record

ArticleAIDS (London, England)2014

Mortality trends in the era of antiretroviral therapy: evidence from the Network for Analysing Longitudinal Population based HIV/AIDS data on Africa (ALPHA).

Georges Reniers, Emma Slaymaker, Jessica Nakiyingi-Miiro, Constance Nyamukapa, Amelia Catharine Crampin, Kobus Herbst, Mark Urassa, Fred Otieno, Simon Gregson, Maquins Sewe and 9 more

Abstract read
In one paragraph

Article in AIDS (London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Serotonin Levels in Newly-Infected HIV-Positive: A Preliminary Study.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2024
    Article
  12. Article
  13. Article
  14. Article
  15. Predictors of All-Cause Mortality Among People With Human Immunodeficiency Virus (HIV) in a Prospective Cohort Study in East Africa and Nigeria.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Georges ReniersaDepartment of Population Health, London School of Hygiene and Tropical Medicine, London, UK bResearch Unit on AIDS, Medical Research Council/Uganda Virus Research Institute, Entebbe, Uganda cManicaland HIV/STD prevention project, Bio-medical Research and Training Institute, Harare, Zimbabwe dKaronga Prevention Study, London School of Hygiene and Tropical Medicine, Chilumba, Malawi eAfrica Centre for Health and Population Studies, University of KwaZulu Natal, Somkhele, South Africa fTAZAMA project, National Institute for Medical Research, Mwanza, Tanzania gKenya Medical Research Institute / Centers for Disease Control and Prevention, Kisumu, Kenya hSchool of Public Health, Faculty of Medicine, Imperial College, London, UK iRakai Health Sciences Program, Makerere University School of Public Health, Rakai, Uganda jDepartment of Social Statistics and Demography, Southampton University, Southampton, UK.
Emma Slaymaker
Jessica Nakiyingi-Miiro
Constance Nyamukapa
Amelia Catharine Crampin
Kobus Herbst
Mark Urassa
Fred Otieno
Simon Gregson
Maquins Sewe
Denna Michael
Tom Lutalo
Victoria Hosegood
Ivan Kasamba
Alison Price
Dorean Nabukalu
Estelle Mclean
Basia Zaba
ALPHA Network

Funding

Wellcome Trust 085477/Z/08/ZWellcome Trust 098610
6 · The paper itself

Abstract

backgroundThe rollout of antiretroviral therapy (ART) is one of the largest public health interventions in Eastern and Southern Africa of recent years. Its impact is well described in clinical cohort studies, but population-based evidence is rare.

methodsWe use data from seven demographic surveillance sites that also conduct community-based HIV testing and collect information on the uptake of HIV services. We present crude death rates of adults (aged 15-64) for the period 2000-2011 by sex, HIV status, and treatment status. Parametric survival models are used to estimate age-adjusted trends in the mortality rates of people living with HIV (PLHIV) before and after the introduction of ART.

resultsThe pooled ALPHA Network dataset contains 2.4 million person-years of follow-up time, and 39114 deaths (6893 to PLHIV). The mortality rates of PLHIV have been relatively static before the availability of ART. Mortality declined rapidly thereafter, with typical declines between 10 and 20% per annum. Compared with the pre-ART era, the total decline in mortality rates of PLHIV exceeds 58% in all study sites with available data, and amounts to 84% for women in Masaka (Uganda). Mortality declines have been larger for women than for men; a result that is statistically significant in five sites. Apart from the early phase of treatment scale up, when the mortality of PLHIV on ART was often very high, mortality declines have been observed in PLHIV both on and off ART.

conclusionThe expansion of treatment has had a large and pervasive effect on adult mortality. Mortality declines have been more pronounced for women, a factor that is often attributed to women's greater engagement with HIV services. Improvements in the timing of ART initiation have contributed to mortality reductions in PLHIV on ART, but also among those who have not (yet) started treatment because they are increasingly selected for early stage disease.

Indexed as

Drug UtilizationAdolescentAdultAfricaAnti-Retroviral AgentsAntiretroviral Therapy, Highly ActiveFemaleHIV InfectionsHumansIncidenceMaleMiddle AgedSex FactorsSurvival AnalysisYoung AdultAnti-Retroviral Agents

Identifiers

PMID25406756
PMCPMC4251911

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.